Share this post on:

Product Name :
Recombinant human tissue-type plasminogen activator derivative (Shanghai Fudan-Zhangjiang/Shandong Ahua)

Search keywords :
Reteplase

drugId :
null

Target Vo:
Plasminogen

Target Vo Short Name :
PLG

Moa_Name:
Plasminogen stimulants

First Approval Country :
Mainland China

First Approval Date Filter:
2007

Origin Company_Name :
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Active Company_Name :
China Resources Angde Biotech Pharma Co Ltd

Active Indication_Name:
Myocardial Infarction

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
p-RIPK1(S166) Antibody (YA1284) manufacturer
Trastuzumab emtansine (solution) EGFR
ZO-1/TJP1 Antibody: ZO-1/TJP1 Antibody is an unconjugated, approximately 191 kDa, rabbit-derived, anti-ZO-1/TJP1 polyclonal antibody. ZO-1/TJP1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, pig, and predicted: mouse, rat, chicken, dog, cow, rabbit, guinea pig background without labeling.

Share this post on:

Author: Interleukin Related